WO2006082115A1 - Set of disposable bags for viral inactivation of biological fluids - Google Patents
Set of disposable bags for viral inactivation of biological fluids Download PDFInfo
- Publication number
- WO2006082115A1 WO2006082115A1 PCT/EP2006/001455 EP2006001455W WO2006082115A1 WO 2006082115 A1 WO2006082115 A1 WO 2006082115A1 EP 2006001455 W EP2006001455 W EP 2006001455W WO 2006082115 A1 WO2006082115 A1 WO 2006082115A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bag
- viral inactivation
- plasma
- facility
- funnel
- Prior art date
Links
- 230000002779 inactivation Effects 0.000 title claims abstract description 175
- 230000003612 virological effect Effects 0.000 title claims abstract description 159
- 239000013060 biological fluid Substances 0.000 title claims abstract description 63
- 238000004440 column chromatography Methods 0.000 claims abstract description 27
- 238000011084 recovery Methods 0.000 claims abstract description 16
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 210000002381 plasma Anatomy 0.000 claims description 224
- 239000003921 oil Substances 0.000 claims description 133
- 235000019198 oils Nutrition 0.000 claims description 133
- 238000000605 extraction Methods 0.000 claims description 55
- 238000000034 method Methods 0.000 claims description 54
- 239000003599 detergent Substances 0.000 claims description 39
- 239000002904 solvent Substances 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 35
- 238000000926 separation method Methods 0.000 claims description 27
- 239000004359 castor oil Substances 0.000 claims description 24
- 235000019438 castor oil Nutrition 0.000 claims description 24
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 24
- 238000011282 treatment Methods 0.000 claims description 24
- 210000004369 blood Anatomy 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 15
- 230000005526 G1 to G0 transition Effects 0.000 claims description 14
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- -1 polyoxyethylene Polymers 0.000 claims description 9
- 239000002244 precipitate Substances 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 6
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 claims description 6
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 claims description 6
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 5
- 229960000907 methylthioninium chloride Drugs 0.000 claims description 5
- 239000004800 polyvinyl chloride Substances 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- ISAVYTVYFVQUDY-UHFFFAOYSA-N 4-tert-Octylphenol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 ISAVYTVYFVQUDY-UHFFFAOYSA-N 0.000 claims description 3
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 3
- 235000019486 Sunflower oil Nutrition 0.000 claims description 3
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 claims description 3
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 claims description 3
- 235000012343 cottonseed oil Nutrition 0.000 claims description 3
- 239000002385 cottonseed oil Substances 0.000 claims description 3
- 229960002446 octanoic acid Drugs 0.000 claims description 3
- 229960002477 riboflavin Drugs 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 239000003549 soybean oil Substances 0.000 claims description 3
- 235000012424 soybean oil Nutrition 0.000 claims description 3
- 239000002600 sunflower oil Substances 0.000 claims description 3
- 229940113164 trimyristin Drugs 0.000 claims description 3
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 claims description 3
- 229940117972 triolein Drugs 0.000 claims description 3
- 229960001947 tripalmitin Drugs 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- JYFHYPJRHGVZDY-UHFFFAOYSA-N Dibutyl phosphate Chemical compound CCCCOP(O)(=O)OCCCC JYFHYPJRHGVZDY-UHFFFAOYSA-N 0.000 claims description 2
- FCASKLHVRFDIJB-UHFFFAOYSA-N Riboflavine Natural products Cc1cc2N=C3C(NC(=O)NC3=O)N(CC(O)C(O)C(O)CO)c2cc1C FCASKLHVRFDIJB-UHFFFAOYSA-N 0.000 claims description 2
- GTVWRXDRKAHEAD-UHFFFAOYSA-N Tris(2-ethylhexyl) phosphate Chemical compound CCCCC(CC)COP(=O)(OCC(CC)CCCC)OCC(CC)CCCC GTVWRXDRKAHEAD-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 238000010306 acid treatment Methods 0.000 claims description 2
- 238000010261 blood fractionation Methods 0.000 claims description 2
- 238000013375 chromatographic separation Methods 0.000 claims description 2
- 229960003964 deoxycholic acid Drugs 0.000 claims description 2
- SEGLCEQVOFDUPX-UHFFFAOYSA-N di-(2-ethylhexyl)phosphoric acid Chemical compound CCCCC(CC)COP(O)(=O)OCC(CC)CCCC SEGLCEQVOFDUPX-UHFFFAOYSA-N 0.000 claims description 2
- NAIBHQRYLPOHGG-UHFFFAOYSA-N dibutyl ethyl phosphate Chemical compound CCCCOP(=O)(OCC)OCCCC NAIBHQRYLPOHGG-UHFFFAOYSA-N 0.000 claims description 2
- QHAUASBJFFBWMY-UHFFFAOYSA-N didecyl hydrogen phosphate Chemical compound CCCCCCCCCCOP(O)(=O)OCCCCCCCCCC QHAUASBJFFBWMY-UHFFFAOYSA-N 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- HUDSKKNIXMSHSZ-UHFFFAOYSA-N dihexyl hydrogen phosphate Chemical compound CCCCCCOP(O)(=O)OCCCCCC HUDSKKNIXMSHSZ-UHFFFAOYSA-N 0.000 claims description 2
- YEWZQCDRZRYAEB-UHFFFAOYSA-N ditert-butyl hydrogen phosphate Chemical compound CC(C)(C)OP(O)(=O)OC(C)(C)C YEWZQCDRZRYAEB-UHFFFAOYSA-N 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 230000036512 infertility Effects 0.000 claims description 2
- 235000019192 riboflavin Nutrition 0.000 claims description 2
- 239000002151 riboflavin Substances 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- SFENPMLASUEABX-UHFFFAOYSA-N trihexyl phosphate Chemical compound CCCCCCOP(=O)(OCCCCCC)OCCCCCC SFENPMLASUEABX-UHFFFAOYSA-N 0.000 claims description 2
- KUHPLTBUBAGTDV-UHFFFAOYSA-N tris-decyl phosphate Chemical compound CCCCCCCCCCOP(=O)(OCCCCCCCCCC)OCCCCCCCCCC KUHPLTBUBAGTDV-UHFFFAOYSA-N 0.000 claims description 2
- CQXYINNETWHZTR-UHFFFAOYSA-N tritert-butyl phosphate Chemical compound CC(C)(C)OP(=O)(OC(C)(C)C)OC(C)(C)C CQXYINNETWHZTR-UHFFFAOYSA-N 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 claims 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims 1
- 229920000915 polyvinyl chloride Polymers 0.000 claims 1
- 229920004890 Triton X-100 Polymers 0.000 description 33
- 239000013504 Triton X-100 Substances 0.000 description 33
- 230000005484 gravity Effects 0.000 description 27
- 229920004897 Triton X-45 Polymers 0.000 description 23
- 230000015572 biosynthetic process Effects 0.000 description 21
- 239000000839 emulsion Substances 0.000 description 21
- 239000000463 material Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 239000000126 substance Substances 0.000 description 17
- 238000002156 mixing Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 230000008569 process Effects 0.000 description 14
- 239000003634 thrombocyte concentrate Substances 0.000 description 14
- 108010054218 Factor VIII Proteins 0.000 description 13
- 102000001690 Factor VIII Human genes 0.000 description 13
- 229960000301 factor viii Drugs 0.000 description 13
- 239000000701 coagulant Substances 0.000 description 10
- 108010047303 von Willebrand Factor Proteins 0.000 description 10
- 102100026735 Coagulation factor VIII Human genes 0.000 description 9
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 9
- 230000035790 physiological processes and functions Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 9
- 238000012546 transfer Methods 0.000 description 8
- 102100036537 von Willebrand factor Human genes 0.000 description 8
- 229960001134 von willebrand factor Drugs 0.000 description 8
- 238000002617 apheresis Methods 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 238000010606 normalization Methods 0.000 description 7
- 230000005501 phase interface Effects 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 108010049003 Fibrinogen Proteins 0.000 description 6
- 102000008946 Fibrinogen Human genes 0.000 description 6
- 229940012952 fibrinogen Drugs 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 241000711549 Hepacivirus C Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 238000011049 filling Methods 0.000 description 5
- 230000000415 inactivating effect Effects 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- 102100022641 Coagulation factor IX Human genes 0.000 description 4
- 108010076282 Factor IX Proteins 0.000 description 4
- 108010066124 Protein S Proteins 0.000 description 4
- 229940096437 Protein S Drugs 0.000 description 4
- 102000029301 Protein S Human genes 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 229960004222 factor ix Drugs 0.000 description 4
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 102100023804 Coagulation factor VII Human genes 0.000 description 3
- 108010023321 Factor VII Proteins 0.000 description 3
- 101800004937 Protein C Proteins 0.000 description 3
- 102000017975 Protein C Human genes 0.000 description 3
- 101800001700 Saposin-D Proteins 0.000 description 3
- 108090000183 alpha-2-Antiplasmin Proteins 0.000 description 3
- 102000003801 alpha-2-Antiplasmin Human genes 0.000 description 3
- 229940012413 factor vii Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 244000309711 non-enveloped viruses Species 0.000 description 3
- 229960000856 protein c Drugs 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 235000003846 Ricinus Nutrition 0.000 description 2
- 241000322381 Ricinus <louse> Species 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 229940024790 prothrombin complex concentrate Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 238000003466 welding Methods 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- AJDONJVWDSZZQF-UHFFFAOYSA-N 1-(2,4,4-trimethylpentan-2-yl)-4-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]benzene Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OC1=CC=C(C(C)(C)CC(C)(C)C)C=C1 AJDONJVWDSZZQF-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108091006522 Anion exchangers Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000702617 Human parvovirus B19 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 239000012614 Q-Sepharose Substances 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002506 anticoagulant protein Substances 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000011194 good manufacturing practice Methods 0.000 description 1
- 239000012760 heat stabilizer Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000012994 industrial processing Methods 0.000 description 1
- 239000004434 industrial solvent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/10—Bag-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
- A61L2/0088—Liquid substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/10—Bag-type containers
- A61J1/12—Bag-type containers with means for holding samples of contents
Definitions
- the present invention concerns a set system of disposable bags comprising a viral inactivation bag and a method in which the set of disposable bags is used, optionally in combination with other bags and devices for further purification and manufacture of therapeutic proteins .
- the invention relates to viral inactivation of biological fluids , under aseptic conditions , such as human or animal blood plasma, blood serum and plasma fractions in the form of single units or small pools .
- Human and animal blood plasma and plasma fractions play an important role in modern medicine . They are mainly used for transfusion purposes in the treatment of bleeding episodes , infectious episodes, or for prophylaxis or for pre-treating patients prior to surgery in certain clinical situations .
- a maj or drawback in the use of human or animal blood plasma or plasma fractions is the risk of transmission of blood borne viruses , such as human immunodeficiency virus
- HIV hepatitis B virus
- HCV hepatitis C virus
- West Nile Virus West Nile Virus
- U. S . patent No . 4 , 789 , 545 discloses a method for removal of organic solvent/detergent combinations , or solvent alone , from plasma and plasma products by partition into ⁇ innocuous natural oils or synthetic triglycerides .
- U. S . patent No . 5 , 094 , 960 describes the removal of solvent/detergent combinations, from plasma or plasma products by hydrophobic interaction chromatography under mild conditions, i . e . at the native concentrations of proteins , salts and other physiologic constituents .
- Solvent/detergent or solvent alone treatment under appropriate conditions of reagent concentration, temperature and contact time effectively disassembles viruses that have envelope proteins associated with lipids , while having negligible effect on the molecular conformations and biological activity of sensitive plasma proteins .
- the viral inactivation of human plasma by solvent/detergent , or solvent alone treatment has always involved the treatment of large pools of a large number of donations (100 to 500 litres , or more) and has required large and expensive pharmaceutical manufacturing facilities .
- the solvent/detergent , or solvent alone, treatment is not effective against non-enveloped viruses , such as the currently known plasma-borne viruses parvovirus B19 or hepatitis A virus (HAV) . Therefore, if one of the donations of the plasma pool is contaminated by a non-enveloped virus , the whole pool will be contaminated.
- One of the obj ectives of the present invention is to provide for a convenient , easy- to-use and cost-effective means that allows for the viral inactivation of small pools of biological fluids , such as blood plasma or plasma fractions . It is a further object to avoid protein denaturation and loss in protein activity.
- a set of disposable bags comprising at least one viral inactivation bag, comprising an inner compartment , an inlet facility and an outlet facility, which are both connected to the inner compartment , the shape of the bag being characterised in that the inner compartment has an
- ovoid longitudinal section and optionally this bag can be connected to other processing devices such as a set of one or several funnel bags , and/or various protein adsorption bags , and/or various protein processing bags , and/or various chromatographic adsorption bag or column
- the different bags or processing systems being connectable with each other to maintain bacterial sterility during the processing step and reduce
- the ovoid longitudinal section of the viral inactivation bag is elliptic .
- the elliptical longitudinal section has first horizontal axis a and a second vertical axis b, whereby the ratio a/b is greater than X .
- the terms 5 horizontal and vertical are used with respect to the position of the bag in use where the outlet facility is directed vertically downwards .
- the ovoid, preferably elliptic longitudinal section of the inner compartment has the advantage of not having any angles , which could hold back some of the biological fluid and avoid the total extensive mixing of the fluid with the viral inactivating agents .
- the viral inactivation bag is made of a therapeutically acceptable and flexible material .
- flexible material is understood a material that can be deformed when submitted to pressure or stress, for example due to filling and shaking the bag .
- the material should maintain its flexibility at temperatures in the range of 5°C to 60 0 C, more particularly in the range of 20 to 37 0 C that is commonly used to carry out viral inactivation treatment by the solvent/detergent combination or solvent alone .
- a suitable material is a material which is suitable for contact with blood and plasma products and derivatives thereof , for example conventional medical/pharmaceutical grade polyvinyl chloride (PVC) , as used in the blood and plasma industry.
- PVC polyvinyl chloride
- the viral inactivation bag is preferably made of two laminated sheets of the therapeutically acceptable and flexible material , the two sheets being welded together on their periphery in order to form an ovoid inner compartment comprising at least two apertures for the inlet facilities and one for the outlet facility, respectively .
- the welding should resist to the pressure and stress produced by the biological fluid, especially when filling and shaking the bag .
- the sheets are welded together e . g . by ultrasonic sealing or radio frequency (high energy) sealing in order to avoid contamination of the inner compartment with chemical . products .
- the viral inactivation bag comprises one at least translucent portion adj acent to the outlet facility .
- the whole bag is translucent .
- the viral inactivation bag is equipped with means for suspending the bag vertically, the outlet facility showing downwards .
- the means for suspending the bag are arranged in the region of the upper periphery of the bag so that the bag can be hung up or laid ' without deformation . It can also be equipped with means for lying it horizontally (e . g . for the viral inactivation step under controlled temperature and mild shaking) .
- the volume of the inner compartment depends on the quantity of biological fluid to be treated .
- the volume of the inner compartment is in the range from 50 ml to 20 1 , preferably in the range from 50 ml to 5000 ml , more preferably from 100 ml to 3000 ml , and even more preferably in the range from 200 ml to 2000 ml depending upon the plasma or plasma fraction to be virally-inactivated or the number of plasma units used as the starting pool .
- the inlet facility and the outlet facility are preferably arranged on opposite sides of the viral inactivation bag .
- the inlet facility comprises two ports, a first port for the transfer of the biological fluid and a second port for the addition of process chemicals .
- process chemical is understood any chemical product used during viral inactivation .
- the first port is provided with at least one state of the art bag spike or Luer-lock, e . g . one, or two, or three bag spikes or Luer-locks , in order to allow for an easy transfer of the biological fluid from a storage or collection bag into the viral inactivation bag.
- the outlet facility allows the transfer from the viral inactivation bag to another container, for example a disposable funnel bag directly or by means of a flexible tube .
- the disposable funnel bag used for the removal of the viral inactivating agent (s) comprises an inner compartment , an inlet facility and an outlet facility, which are both connected to the inner compartment , characterized in that the inner compartment has a funnel- like lower portion that meets the outlet facility and the inner compartment contains a separation agent .
- the inner compartment of the funnel bag has a longitudinal section which comprises a lower portion of essentially triangular shape , the triangle being formed by the lower limitations of the longitudinal section of the inner compartment .
- the lower limitations are essentially linear and enclose an angle ⁇ of 15° to 170° , preferably 30 ° to 150 ° and even more preferably of 50 ° to 130° ; e . g . 120 ° . This angle ⁇ coincides with the outlet facility of the funnel bag .
- the height of the triangular portion is from 10 to 100 % , preferably 15 to 50 % and even more preferably from 20 to 40 % , e .g . 25 % of the total height between the vertex of the triangle enclosing angle ⁇ and the lower end of the inlet facility of the funnel bag .
- the lower portion of the inner compartment in the form of a funnel has the advantage of allowing an optimized phase separation between e . g . an upper oil phase and the biological fluid containing lower phase as well as a satisfactory, i . e . a regular and constant draining of the content and a well-controlled, potentially machine- assisted separation of biological fraction phase (bottom layer) from the oily phase (top layer) -.
- the funnel bag is made of a therapeutically acceptable and flexible material .
- flexible material is understood a material that can be deformed when submitted to pressure or stress , for example due to filling and shaking the bag .
- the material should maintain its flexibility at temperatures in the range of 5 0 C to 60 0 C, more particularly in the range of 20 to 37 0 C that is the optimal temperature for stability of protein solutions in the absence of heat- stabilizers .
- a suitable material is for example conventional polyvinyl chloride (PVC) for medical/pharmaceutical use .
- the funnel bag can be made of two sheets of the therapeutically acceptable and flexible material that are put congruently on top of each other and welded together on their periphery so that the inner compartment comprising two apertures for the inlet and outlet facilities, respectively, is formed.
- the welding should resist to the pressure and stress produced by the biological fluid, especially when filling and shaking the bag .
- the sheets are welded together by ultrasonic sealing in order to avoid contamination of the inner compartment with chemical products .
- the funnel bag comprises one at least translucent portion adj acent to the outlet facility.
- the whole bag is translucent .
- the funnel bag is equipped with means for suspending the bag vertically, the outlet facility showing downwards .
- the means for suspending the bag are arranged in the region of the upper periphery of the bag so that the bag can be hung up without deformation .
- the volume of the inner compartment depends essentially on the volume of the process chemicals containing biological fluid .
- the volume of the inner compartment is 10% larger than that of the viral inactivation bag , and in the range from 55 ml to 22 1 , preferably in the range from, 55 ml to 5500 ml , more preferably in the range from 110 ml to 3300 ml , and even more preferably in the range from 220 ml to 2200 ml depending upon the plasma or plasma fraction to be virally-inactivated or the number of plasma units used as the starting pool .
- the inlet facility and the outlet facility are preferably arranged on opposite sides of the funnel bag .
- the inlet facility comprises a state of the art plasma bag spike in order to allow for an easy transfer of the mixture into the extraction bag .
- the outlet facility of the viral inactivation bag is punctured with the spike and the mixture is transferred into the extraction bag by gravity.
- outlet facility of the viral inactivation bag and inlet facility of the downstream funnel bag may be connected by tubings and controlled by both breakable valves and clamps .
- the outlet facility of the funnel bag is preferably sealed.
- the funnel bag is adapted to contain a sterile pharmaceutical oil grade in order to perform an oil extraction followed by phase separation .
- the oil is sterilized inside the funnel bag prior to the oil extraction, e . g . by autoclaving .
- the pharmaceutical grade oil can be a naturally occurring oil , for example extracted from a plant or an animal , or a synthetic compound of similar structure .
- Suitable naturally occurring oils include castor oil (also known as ricinus oil) , soybean oil , sunflower oil , cottonseed oil .
- a preferred synthetic compound is ⁇ a synthetic triglyceride .
- suitable synthetic triglycerides include triolein, tristearin, tripalmitin, trimyristin, and combinations thereof .
- the amount of pharmaceutical grade oil which is present in the bag is the amount that allows the extraction of at least 80% of lipid soluble process chemicals , the oil being used in an amount from 2 to 20 weight% based on the weight of the biological fluid, preferably from 5 to 15 weight% and more preferably from 5 to 10 weight% , e . g . 7.5 weight% .
- the above-described funnel bag can also be used in combination with a chromatographic stationary phase .
- other forms of disposable bags can also be contemplated .
- the stationary chromatographic phase When the stationary chromatographic phase has been treated in said disposable bag, it is transferred to a disposable column chromatography device .
- Suitable stationary phases that can be used for further processing of the biological products comprise reversed- phase (hydrophobic interaction) matrices as those used for the removal of solvent or detergent viral inactivating agents , or protein adsorption matrices such as ion-exchange (anion and cation) matrices and affinity
- Preferred reversed phase matrices are a C18 silica packing material , or a SDR (solvent-detergent removal) hyper D .
- Preferred anion exchange matrices are , depending upon the protein to be purified, anion-exchangers gels , such as DEAE-Sephadex A- 50 , DEAE-Sepharose FF, Q-Sepharose , DEAE-Toyopearl 650M, DEAE-Hyper D.
- the disposable column chromatography bag device can be used more particularly for the purification of the prothrombin complex concentrate, using DEAE-Sephadex A- 50.
- the column chromatography bag is made of a therapeutically acceptable and semi-rigid material .
- semi-rigid material it is understood a material that -can be deformed when submitted to pressure or stress , for example due to filling and shaking the bag .
- the material should maintain its semi-rigidity at temperatures in the range of 4 0 C to 50 0 C .
- the set of bags according to the invention comprises two viral inactivation bags .
- the use of a second viral inactivation bag further increases the probability that all of the biological fluid gets into contact with the viral inactivation agent , although the use of only one bag already allows a complete viral inactivation.
- the bags of the set of disposable bags according to the invention are connected with each other, for example with flexible tubes .
- the tubes are advantageously equipped with means for stopping and eventually regulating the flow of biological fluid from one bag to another, such as clamps or valves .
- the set of disposable bags comprises at least one, preferably two viral inactivation bags according to the invention, 1 to 3 , preferably 2 , and more preferably 3 , advantageously subsequent , funnel bags according to the invention pre-filled with sterile pharmaceutical grade oil , and a funnel bag according to the invention pre-filled with a stationary phase for column chromatography .
- the bags are connected among each other, i . e . the outlet facility of the viral inactivation bag is connected to the inlet facility of the first funnel bag, the outlet facility of the first funnel bag is connected to the inlet facility of the second funnel bag, the outlet facility of the second funnel bag to the inlet facility of the third funnel bag .
- the outlet facility of the third funnel bag is connected to a chromatographic system.
- chromatographic system is also comprised of plastic bags containing purification buffers or solvents . If the set of disposable bags comprises two viral inactivation bags , the additional viral inactivation bag is introduced before the first viral inactivation bag, i . e . its outlet facility is connected to the inlet facility of the first viral inactivation bag .
- the set of disposable bags comprises at least one , preferably two viral inactivation bags according to the invention, 1 to 3 , preferably 2 , and more preferably 3 , advantageously subsequent , funnel bags according to the invention pre-filled with sterile pharmaceutical grade oil .
- the bags are connected among each other, i . e . the outlet facility of the viral inactivation bag is connected to the inlet facility of the first funnel bag, the outlet facility of " the firs ' t funnel " bag is connected to the inlet facility of the second funnel bag, the outlet facility of the second funnel bag to the inlet facility of the third funnel bag .
- the outlet facility of the third funnel bag is connected to the inlet facility of a fourth bag which does not need to have funnel type shape . If the set of disposable bags comprises two viral inactivation bags , the additional viral inactivation bag is introduced before the first viral inactivation bag, i . e . its outlet facility is connected to the inlet facility of the first viral inactivation bag .
- the set of disposable bags comprises at least one , preferably two viral inactivation bags according to the invention, 1 to 3 , preferably 2 , and more preferably 3 , advantageously subsequent , funnel bags according to the invention pre- filled with pharmaceutical grade oil , and a funnel bag according to the invention pre-filled with a stationary phase for column chromatography.
- the bags are connected among each other, i . e .
- the outlet facility of the viral inactivation bag is connected to the inlet facility of the first funnel bag, the outlet facility of the first funnel bag is connected to the inlet facility of the second funnel bag, the outlet facility of the second funnel bag to the inlet facility of the third funnel bag and the outlet facility of the third funnel bag to the inlet facility of the stationary phase containing funnel bag .
- the outlet facility of the stationary phase containing funnel bag is sealed . If the set of disposable bags comprises two viral inactivation bags, the additional viral inactivation bag is introduced before the first viral inactivation bag, i . e . its outlet facility is connected to the inlet facility of the first viral inactivation bag .
- the bags are connected with flexible tubings .
- the tubings are advantageously equipped with means for stopping and eventually regulating the flow of biological fluid from one bag to another, such as clamps or valves .
- Any equipment or accessories used in or with the set of disposable bags, such as tubings, clamps or valves, are made of medical and pharmaceutical acceptable material .
- the set of disposable bags according to the invention is very flexible in its use . It is space saving, easily transportable and therefore can be employed, wherever viral inactivation of biological fluids may be necessary. In order to use the set of disposable bags , it is not necessary to dispose of any industrial facility such as a pharmaceutical factory . However, this single-use disposable bag system can also be used within the setting of a manufacturing facility to reduce the use of stainless steel equipment and eliminate the need for washing and sterilization during the manufacture of plasma derivatives .
- composition of the set of disposable bags can easily be modified. It can be used with or without funnel bags and/or with or without a column chromatography bag device • in order to. adjust best to the required manufacturing process .
- the number of viral inactivation bags and funnel bags can also be varied. Therefore , the set of bags can be adapted to the individual needs and requirements of every case .
- Another advantage of the set of bags according to the invention is that they are discarded after each use . Thus ⁇ the risk of contamination of other batches is avoided .
- the invention also relates to a method in which the set of disposable bags described above is used. It particularly relates to a method of viral inactivation of a biological fluid comprising the steps of
- Biological fluids according to the present invention comprise mammalian blood, blood plasma, blood serum, plasma fractions , precipitates from blood fractions and supernatants from blood fractionation, platelet poor plasma, cryo-poor plasma (cryosupernatant) .
- Preferred biological fluids are blood plasma, including recovered plasma (plasma from whole blood) and apheresis plasma, cryo-poor plasma, plasma fractions , such as fractions for the purification of factor VIII , Von Willebrand factor, fibrinogen, fibronectin, prothrombin complex, Factor IX, Factor VII , Protein C , .Protein S , Antithrombin, Alpha 1 antitrypsin, Cl -inhibitor, immunoglobulins , albumin, precipitates from plasma, such as cryoprecipitate, polyethylene glycol , caprylic acid, or ammonium sulphate precipitated fractions , and their corresponding supernatants, or any other precipitates or supernatants from plasma fractionation, such as cryosupernatant , supernatant I+II+III , precipitate I+II+III , supernatant II+III , precipitate II+III , supernatant I+III , precipitate II , supern
- Plasma fractions , precipitates and supernatants may be obtained from recovered plasma (plasma from whole blood) as well as from apheresis plasma .
- the volume of recovered plasma from one whole blood donations is usually between 100 and 240 ml
- the volume of a donation of apheresis plasma is usually between 500 and 900 ml .
- a preferred viral inactivation method that can be carried out in the viral inactivation bag according to the invention is the S/D (evolvent/detergent) method, the solvent only method or the detergent only method, wherein the process chemicals that are added to the biological fluid are solvent/detergent combinations , solvent or combinations of solvents alone or detergent or combinations of detergents alone .
- Suitable solvents are di- or trialkylphosphates , such as tri- (n-butyl ) phosphate , tri- (t-butyl ) phosphate, tri- ⁇ n- hexyl) phosphate , tri- (2 -ethylhexyl ) phosphate, tri- (n- decyl ) phosphate , di- (n-butyl ) phosphate, di- (t- butyl) phosphate, di- (n-hexyl) phosphate , di- (2 - ethylhexyl) phosphate , di - (n-decyl) phosphate as well as dialkylphosphates with different alkyl chains .
- di- or trialkylphosphates such as tri- (n-butyl ) phosphate , tri- (t-butyl ) phosphate, tri- ⁇ n- hexyl) phosphate , tri- (2
- Di- or trialkylphosphates having different alkyl chains can be employed, for example ethyl di (n-butyl) phosphate .
- An especially preferred trialkylphosphate is tri- (n- butyl) phosphate (TnBP) .
- detergents are sodium deoxycholate and sulfobetaines , such as N-dodecyl-N, N-dimethyl-2 -
- the solvent if used alone, is used in an amount from 0.1 to 3 weight% with respect to the weight of the biological fluid, preferably 0.3 to 2.5% weight%, and even more preferably 2% weight% .
- the solvent when combined with a detergent is used in an amount from 0.1 to 2 weight% with respect to the weight of the biological fluid, preferably 0.3 to 1 % weight%, and even more preferably 1 % weight% for the viral inactivation of complex mixtures like plasma, cryo-poor plasma, or cryoprecipitate , or 0.3 weight % for the viral inactivation of more purified fractions like Factor VIII .
- the detergent when combined with a solvent is used in an amount from 0.1 to 2 weight% with respect to the weight of the biological fluid, preferably
- the detergent if used alone, is used in an amount from 0.5 to 2 weight% with respect to the weight of the biological fluid, preferably 1 % weight% .
- the biological fluid is treated with the solvent/detergent combination, the solvent or the detergent during a period of 4 to 8 hours , preferably 4 to 6 hours , for example 4 hours for the viral inactivation treatment of plasma, cryo-poor plasma, or cryoprecipitate using e . g . 1% TnBP and 1% Triton X-45 or Triton X-100 , or 6 hours for the viral inactivation treatment of Factor VIII fraction using e .g . 0.3% TnBP and 1% Tween- 80.
- the treatment period is split up between the different bags .
- an overall treatment period of 4.5 hours may be split up between a first and a second bag as follows : 30 min in the first bag and 4 hours in the second bag.
- This distribution of the overall treatment period allows for good observance of good manufacturing practice, since the first bag is used for mixing the biological fluid with the process chemicals and the beginning of the viral inactivation, whereas the second bag is used for the final viral inactivation .
- the solvent and/or detergent can be extracted from the biological fluid by oil extraction with pharmaceutical grade oil .
- the solvent and/or detergent containing biological fluid is preferably transferred into a funnel bag according to the present invention that holds sterile pharmaceutical grade oil .
- the pharmaceutical grade oil can be a naturally occurring oil , for example extracted from a plant or an animal , or a synthetic compound of similar structure .
- Suitable naturally occurring oils include castor oil (also known as ricinus oil ) , soybean oil , sunflower oil , cottonseed oil .
- a preferred synthetic compound is a synthetic triglyceride . Examples of suitable synthetic triglycerides include triolein, tristearin, tripalmitin, trimyristin, and combinations thereof .
- the amount of pharmaceutical grade oil which is present in the bag is the amount that allows the extraction of at least 80% of lipid soluble process chemicals , the oil being used in an amount from 2 to 20 weight% based on the weight of the biological fluid, preferably from 5 to 15 weight% and more preferably from 5 to 12 weight% , e . g . 7.5 or 10 weight% .
- Oil extraction may be carried out once or more , for example 1 to 3 times , preferably twice and more preferably three times , depending in particular on the oil concentration and on the ability of further purification steps to contribute also to removal of the solvent and/or detergent .
- the extraction process could work with 2 weight% oil or less , but the extraction procedure would have to be repeated more times in order to obtain a desired purity of the biological fluid, which is not preferred because it is time consuming and can cause loss of matter .
- the solvent and/or detergent may also be removed from the biological fluid by column chromatography using a funnel bag holding a stationary phase for column chromatography or a disposable chromatographic column device connected to the system according to the present invention, or other chromatographic system.
- the column chromatography may be carried out subsequently to oil extraction or directly after solvent/detergent treatment .
- column chromatography is also used when viralIy inactivating Factor VIII plasma fraction in order to remove the process chemicals used for viral inactivation, purify Factor VIII and concentrate Factor VIII .
- Suitable types of column chromatography comprise anion-exchange immunoaffinity, affinity on immobilized Factor VIII ligands or immobilized heparin .
- column chromatography of viralIy inactivated' Factor VIII is carried out directly after the viral inactivation step without any prior oil extraction .
- the disposable viral inactivation bag according to the present invention can also be used for other viral inactivation methods of biological fluids using other process chemicals , for example methylene blue treatment , riboflavine (vitamin B2 ) treatment , acid pH treatment
- caprylic acid treatment generally at pH ⁇ 6.5.
- Viral inactivating treatment of biological fluids especially plasma, cryo-poor plasma, cryoprecipitate and other plasma fractions , such as Factor VIII plasma fraction, in a set of bags according to the invention allows for viral inactivation of small quantities of biological fluid .
- viral inactivation of single donations or small pools of biological fluids avoids mechanical phenomena, . such as aggregation, complexation, or oxidation phenomena, which all denaturize proteins .
- Another advantage of the treatment of small quantities is that a tailor-made production of virally inactivated biological fluid is possible . Accordingly, a patient could for example be treated with virally inactivated plasma fractions coming exclusively from one donor, or small numbers of donors therefore decreasing the risks of exposure to any plasma-borne infectious agents .
- Another advantage of the treatment as described in the present invention is the possibility to process and virally inactivate virally infected plasma, either as single donation, or as small pools, intended for therapeutic clinical studies , such as HCV positive plasma or SARS positive plasma, or any other potentially infectious plasma that contains neutralizing antibodies susceptible to treat other patients . Accordingly, a patient could for example be treated with virally inactivated HCV positive or SARS positive plasma fractions coming exclusively from one donor, or small numbers of donors therefore eliminating the risks of exposure to HCV or SARS or any plasma-borne infectious agents .
- Figure 1 is a schematic longitudinal section of one embodiment of a viral inactivation bag according to the present invention
- Figure Ia is a schematic longitudinal section of another embodiment of a viral inactivation bag according to the present invention
- Figure Ib is a schematic cross sectional view along the line AA' of the embodiment of Figure 1 when the bag is empty;
- Figure Ic is a schematic cross sectional view along the line AA' of the embodiment of Figure 1 when he bag is filled;
- Figure 2 is a schematic longitudinal section of one embodiment of an extraction bag according to the present invention.
- Figure 2a is a schematic longitudinal section of another embodiment of an extraction bag according to the present invention.
- Figure 2b is a schematic cross-sectional view along the line AA' of the embodiment of Figure 2 when the bag is empty;
- Figure 2c is a schematic cross-sectional view along the line AA' of the embodiment of Figure 2 when the bag is filled;
- Figure 3 is a schematic longitudinal section of one embodiment of a disposable chromatographic column
- Figure 4 is a schematic longitudinal section of one • embodiment of the set of disposable bags according to the present invention
- Figure 5 is a schematic longitudinal section of another embodiment of the set of disposable bags according to the present invention.
- the viral inactivation bag 1 illustrated in figure 1 has an essentially rectangular outer shape , the horizontal sides 2 being longer than the vertical ones 3.
- the bag 1 comprises an inner compartment 4 , an inlet facility 5 and an outlet facility 6.
- the inner compartment 4 has a longitudinal section in the form of an ellipse with a first axis a, and a second axis b .
- the first axis a is parallel to the horizontal sides 2a and
- the second axis b is parallel to its vertical sides 3 , with a ratio a/b >1.
- the inlet 5 and outlet 6 facilities are each separately connected to the inner compartment 4.
- the inlet facility 5 is arranged in the middle of the upper horizontal side 2b and coincides with the second axis b of the ellipse .
- the outlet facility 6 is arranged directly opposed to the inlet facility 5 in the middle of the lower horizontal side 2a and coincides as well with the second axis b of the ellipse .
- the inlet facility 5 comprises a flexible tubular inlet line, a first port 5a being connected to the end of the inlet line and a second port 5b being laterally connected to the inlet line .
- the first port 5a is a bag spike . It is employed to transfer biological fluid from, for example, a storage or collection bag into the inner compartment 4 of the viral inactivation bag 1.
- the second port 5b is a port for the addition of process chemicals .
- the viral inactivation bag 1 is made of two rectangular sheets of conventional medical/pharmaceutical grade polyvinylchloride (PVC) or other adequate material that are laminated and welded together on their periphery so that the inner compartment 4 comprising two apertures for the inlet 5 and outlet 6 facilities respectively is formed .
- PVC polyvinylchloride
- the inner compartment 4 is surrounded by a welded together border area 7 that extends to the limits of the sheets .
- This border area 7 comprises two holes 8 , that are located left and right of the inlet facility.
- the holes 8 serve as means for suspending the bag 1 vertically .
- Figure Ia illustrates an alternative embodiment of a viral inactivation bag 1 according to the invention.
- the viral inactivation bag 1 of Figure Ia differs from the bag of Figure 1 only in that its inlet facility 5 does not comprise a first 5a and a second port 5b, but in that the bag 1 comprises a second inlet facility Ia which is arranged next to the inlet facility 5 on the upper horizontal side 2b .
- the first inlet facility 5 is used for the addition of process chemicals and the second inlet facility Ia is used for the transfer of biological fluid into the viral inactivation bag 1.
- the inlet facility 5 is sealed with a sealing device 5c which is suitable to be perforated, for example by a needle or canula .
- the inlet facility Ia of the viral inactivation bag 1 comprises a state of the art tube clamp Ic.
- the outlet facility 6 of the viral inactivation bag 1 comprises a state of the art breakable valve 6a .
- Figure Ib illustrates an empty viral inactivation bag 1.
- Figure Ic the same bag is filled and the sheets are separated and bulged outwardly .
- the thickness c of the filled bag is smaller than the smallest of the two axis a and b.
- the funnel bag 9 illustrated in Figure 2 comprises an inner compartment 10 , an inlet facility 11 and an outlet facility 12.
- the inlet 11 and outlet 12 facilities are each separately connected to the inner compartment 10 and are arranged on opposite sides of the .bag 9.
- the inner compartment comprises a funnel-like lower portion 10 a .
- the inlet facility 11 comprises a flexible tubular inlet line connected at one end to the inner compartment 10 and at the other end to a state of the art plasma bag spike . In this way, the process chemicals containing biological fluid can easily be transferred into the funnel bag 9 by gravity from, for example, a viral inactivation bag 1.
- the funnel bag 9 is made of two sheets of conventional medical/pharmaceutical grade polyvinylchloride (PVC) or other adequate material that are laminated and welded together on their periphery so that the inner compartment 10 comprising two apertures for the inlet 11 and outlet 12 facilities respectively is formed.
- PVC polyvinylchloride
- the inner compartment 10 is surrounded by a welded together border area 13 that extends to the limits of the sheets .
- This border area 13 comprises two holes 14 , that are located left and right of the inlet facility1
- the holes 14 serve as means for suspending the bag 9 vertically.
- Figure 2a illustrates a preferred embodiment of a funnel bag 9 according to the invention .
- the inner compartment 10 of the funnel bag 9 has a longitudinal section which comprises a lower portion 10a of . essentially triangular form, the triangle being formed by the lower limitations c and d of the longitudinal section of the inner compartment 10.
- the lower limitations c and d are essentially linear and enclose an angle ⁇ of about 125° . This angle ⁇ coincides with the outlet facility 12 of the funnel bag 9.
- the height h tr i of the triangular portion is about 1/3 of the total height h between the vertex of the triangle enclosing angle ⁇ and the lower end 11a of the inlet facility 11 of the funnel bag 9.
- the funnel bag 9 comprises an additional port 9a .
- the port is sealed with a sealing device 9c which is suitable to be perforated, for example by a needle or canula .
- the inlet facility 11 of the funnel bag 9 comprises a state of the art tube clamp Hc-.
- the outlet facility 12 of the funnel bag 9 comprises a state of the art breakable valve 12a.
- Figure 2b illustrates an empty funnel bag 9.
- Figure 2c the same bag is filled and the sheets are separated and bulged outwardly.
- the disposable chromatographic column bag device 15 represented in Figure 3 comprises a cylindrical hollow body 16 filled with a stationary chromatographic phase , the lower part of the hollow body is provided with a filter 17.
- the cylindrical body is provided with an inlet facility 18 in its higher end and with an outlet facility 19 at its opposed lower end .
- the inlet facility comprises three ports ( 18a, 18b, 18c)
- the outlet facility also comprises three ports (19a , 19b and 19c) .
- the set of disposable bags illustrated in Figure 4 comprises a viral inactivation bag 1 according to the invention, three subsequent funnel bags 9 according to the invention pre-filled with pharmaceutical grade oil (the oil not being represented) , and a funnel bag 9 according to the invention pre-filled with a stationary- phase for column chromat.ography .
- the bags are connected to each other with flexible tubes , i . e .
- the outlet facility 6 of the viral inactivation bag 1 is connected to the inlet facility 11 of the first funnel bag 9
- the outlet facility 12 of the first bag 9 is connected to the inlet facility 11 of the second funnel bag 9
- the outlet facility 12 of the second funnel bag 9 to the inlet facility 11 of the third funnel bag 9
- the outlet facility 12 of the third funnel bag 9 to the inlet facility 11 of the stationary phase containing funnel bag 9.
- the outlet facility 12 of the stationary -phase containing funnel bag 9 is sealed.
- the first port 5a of the inlet facility 5 of the viral inactivation bag 1 of the set of bags of Figure 4 is used for the transfer of the biological fluid into said viral inactivation bag 1.
- the biological fluid may directly be pooled in the first viral inactivation bag 1 by transferring it from one or more collection bags .
- the set of disposable bags illustrated in Figure 5 comprises two viral inactivation bags 1 according to the embodiment of Figure Ia , three subsequent funnel bags 9 according to the embodiment of Figure 2a pre-filled with pharmaceutical grade oil (the oil not being represented) , and a classic blood bag 20 for collecting the virally inactivated biological fluid .
- the bags are connected to each other with flexible tubes , i . e .
- the outlet facility 6 of the first viral inactivation bag 1 is connected to the inlet facility Ia of the second viral inactivation bag 1
- the outlet facility 6 of the second viral inactivation bag 1 to the inlet facility 11 of the first funnel bag 9
- the outlet facility 12 of the first bag 9 is connected to the inlet facility 11 of the second funnel bag 9
- the outlet facility 12 of the second funnel bag 9 to the inlet facility 11 of the third funnel • bag 9
- the outlet facility 12 of the third funnel bag 9 to the inlet facility 21 of the classic blood bag 20.
- the inlet facility Ia of the first viral inactivation bag 1 of the set of bags of Figure 5 is used for the transfer of the biological fluid into said viral inactivation bag 1.
- the biological fluid may directly be pooled in the first viral inactivation bag 1 by transferring it from one or more collection or storage bags .
- the inlet facilities Ia, 11 , 21 of the viral inactivation bags 1 , funnel bags 9 and the classic blood bag 20 respectively comprise each a state of the art tube clamp Ic, lie , 21c.
- the outlet facilities 6 , 12 of the viral inactivation bags 1 and funnel bags 9 respectively comprise each a state of the art breakable valve 6a, 12a.
- EXAMPLE 1 Viral inactivation of 1915 ml apheresis plasma using 2% TnBP
- Apheresis plasma from three donations of about 650 ml is transferred into a sterile, single 2000 ml viral inactivation bag according to Figure 1 , and the bag is heated to 31 °C +/- I 0 C.
- TnBP tri (n-butyl) phosphate
- the TnBP solution is added with the syringe (via the second port of the inactivation bag) slowly over 30 minutes to the plasma .
- the inactivation bag is under gentle shaking, such as using a platelet concentrate shaker device until a final concentration of 2% of the total plasma weight is reached .
- the tubing of the inlet facility is heat-sealed in order to isolate the inactivation bag . Then, vigorous mixing is performed for 30 sec, and the bag is maintained at 31 0 C +/- I 0 C for 4 hrs under gentle stirring such as using a platelet concentrate shaker device or any other appropriate device ensuring mild constant mixing of the plasma/SD mixture .
- the plasma is then transferred into a funnel bag according to Figure 2 containing 100 ml of pharmaceutical grade castor oil .
- the outlet facility of the viral inactivation bag is pierced with the spike of the inlet facility of the funnel bag and the TnBP containing plasma is transferred by gravity .
- the oil/plasma mixture is shaken vigorously until the formation of an emulsion for about one minute , then gently for 15 minutes at room temperature in order to extract TnBP with the oil .
- the funnel bag is then hung up for about 30 min in order to allow for separation of a lower plasma phase and an upper TnBP containing oil phase .
- the lower layer is drained by gravity through the outlet facility into a second funnel bag containing 150 ml of pharmaceutical grade castor oil .
- the oil/plasma mixture in the second funnel bag is shaken vigorously until the formation of an emulsion for about one minute, then gently for 15 minutes at room temperature in order to extract further TnBP with the oil .
- the second funnel bag is then hung up for about 30 min in order to allow for separation of a lower plasma phase and an upper TnBP containing oil phase .
- the lower plasma layer is drained by gravity through the outlet facility into a third funnel bag containing 150 ml of pharmaceutical grade castor oil .
- the phase interface is detected with a UV detector that is arranged on the level of the outlet facility of the second funnel bag .
- the oil/plasma mixture in the third funnel bag is shaken vigorously until the formation of an emulsion for about one minute, then gently for 15 minutes at room temperature in order to extract further TnBP with the oil .
- the third funnel bag is then hung up for about 30 min in order to allow for separation of a lower plasma phase and an upper TnBP containing oil phase .
- the lower plasma layer is drained by gravity through the outlet facility into a classical plasma storage bag.
- Recovered plasma from one donation of about 200 ml is transferred into a sterile , single 200 ml viral inactivation bag according to Figure 1 , and the bag is heated to 31 0 C +/- I 0 C .
- TnBP tri (n-butyl) phosphate
- the TnBP solution is added with the syringe (via the second port of the inactivation bag) slowly over 30 minutes to the plasma .
- the inactivation bag is under gentle shaking, such as using a platelet concentrate shaker device until a final concentration of 2% of the total plasma weight is reached .
- the tubing of the inlet facility is heat-sealed in order to isolate the inactivation bag .
- the plasma is then transferred into a funnel bag according to Figure 2 containing 10 ml pharmaceutical grade castor oil .
- the outlet facility of the viral inactivation bag is pierced with the spike of the inlet facility of the funnel bag and the TnBP containing plasma is transferred by gravity.
- the oil/plasma mixture is shaken vigorously until the formation of an emulsion for about one minute , then gently for 15 minutes at room temperature in order to extract TnBP using the oil .
- the funnel bag is then hung up in order to allow for separation of a lower plasma phase and an upper TnBP containing oil phase .
- the lower layer is drained by gravity through the outlet facility into a second funnel bag containing 10 ml of pharmaceutical grade castor oil .
- the oil/plasma mixture in the second funnel bag is shaken vigorously until the formation of an emulsion for .about one minute , then gently for 15 minutes at room temperature in order to extract further TnBP with the oil .
- the second funnel bag is then hung up in order to allow for separation of a lower plasma phase and an upper TnBP containing oil phase .
- the lower plasma layer is drained by gravity through the outlet facility into a third funnel bag containing 10 ml of pharmaceutical grade castor oil .
- the phase interface is detected with the naked eye .
- the oil/plasma mixture in the third funnel bag is shaken vigorously until the formation of an emulsion for about one minute, then gently for 15 minutes at room temperature in order to extract further TnBP with the oil .
- the third funnel bag is then hung up in order to allow for separation of a lower plasma phase and an upper TnBP containing oil phase .
- the lower plasma layer is drained by gravity through the outlet facility into a classical plasma storage bag .
- the TnBP is measured in the plasma after each extraction step :
- the PT, APTT, INR (international normalized ratio) , and FVIII and FIX physiological functions are also determined at all steps :
- Apheresis plasma from one donation of about 200 ml is transferred into a sterile , single 200 ml viral inactivation bag according to Figure 1 and the bag is heated to 31 0 C +/ - I 0 C .
- TnBP tri (n-butyl) phosphate
- the TnBP solution is added with the syringe (via the second port of the inactivation bag) slowly over 30 minutes to the plasma .
- the viral inactivation bag is under gentle shaking, such as using a platelet concentrate shaker device of the bag until a final concentration of 2% of the total plasma weight is reached .
- the tubing of the inlet facility is heat sealed in order to isolate the inactivation bag .
- the bag is maintained at 31 0 C +/- 1 °C for 4 hrs under gentle stirring such as using a platelet concentrate shaker device or any other appropriate device ensuring mild constant mixing of the plasma/SD mixture .
- the plasma is then transferred into a funnel bag according to Figure 2 containing 10 ml of pharmaceutical grade castor oil .
- the outlet facility of the viral inactivation bag is pierced with the spike of the inlet facility of the funnel bag and the TnBP containing plasma is transferred by gravity.
- the oil/plasma mixture is shaken vigorously until the formation of an emulsion for about one minute, then gently for 15 minutes at room temperature in order to extract TnBP using the oil .
- the funnel bag is then hung up for about 30 min in order to allow for separation of a lower plasma phase and an upper TnBP containing oil phase .
- the lower layer is drained by gravity through the outlet facility into a second funnel bag containing 10 ml of pharmaceutical grade castor oil .
- the oil/plasma mixture in the second funnel bag is shaken vigorously until the formation of an emulsion for about one minute, then gently for 15 minutes at room temperature in order to extract further TnBP with the oil .
- the second funnel bag is then hung up in order to allow for separation of a lower plasma phase and an upper TnBP ' containing oil phase .
- the lower plasma layer is drained by gravity through the outlet facility into a third funnel bag containing IO -ml of pharmaceutical grade castor oil .
- the phase interface is detected with the naked eye .
- the oil/plasma mixture in the third funnel bag is shaken vigorously until the formation of an emulsion for about one minute , then gently for 15 minutes at room temperature in order to extract further TnBP with the oil .
- the third funnel bag is then hung up in order to allow for separation of a lower plasma phase and an upper TnBP containing oil phase .
- the lower plasma layer is drained by gravity through the outlet facility into a classical plasma storage bag .
- Recovered plasma from one donation of about 200 ml is transferred into a sterile , single 200 ml viral inactivation bag according to Figure 1 and the bag is heated to 31°C +/- I 0 C .
- a 1 : 1 solution of pure tri (n-butyl) phosphate (TnBP) and Triton X-45 is pre-filled into a sterile syringe .
- the TnBP/Triton X-45 solution is added with the syringe (via the second port of the inactivation bag) slowly over 30 minutes to the plasma .
- the inactivation bag is under gentle shaking, such as using a platelet concentrate shaker device until a final concentration of 1% TnBP and 1% Triton X-45 of the total plasma weight is reached .
- the tubing of the inlet facility is heat-sealed in order to isolate the inactivation bag .
- the plasma is then transferred into a funnel bag according to Figure 2 containing 15 ml ( i .e . 7.5 wt% with respect to the weight of the plasma) of pharmaceutical grade castor oil .
- the outlet facility of the viral inactivation bag is pierced with the spike of the inlet facility of the funnel bag and the TnBP and Triton X-45 containing plasma is transferred by gravity .
- the oil/plasma mixture is shaken vigorously until the formation of an emulsion for about one minute, then gently for 15 minutes at room temperature in order to extract TnBP and Triton X-45 using the oil .
- the funnel bag is then hung up in order to allow for separation of a lower plasma phase and an upper TnBP and Triton X-45 containing oil phase .
- the lower layer is drained by gravity through the outlet facility into a second funnel bag containing 15 ml of pharmaceutical grade castor oil .
- the phase interface is detected with the naked eye .
- the oil/plasma mixture in the second funnel bag is shaken vigorously until the formation of an emulsion for about one minute , then gently for 15 minutes at room temperature in order to extract further TnBP and Triton X-45 with the oil .
- the second funnel bag is then hung up in order to allow for separation of a lower plasma phase and an upper TnBP and Triton X-45 containing oil phase .
- the lower plasma layer is drained by gravity through the outlet facility into a third funnel bag containing 15 ml of pharmaceutical grade castor oil .
- the oil/plasma mixture in the third funnel bag is shaken vigorously until the formation of an emulsion for about one minute, then gently for 15 minutes at room temperature in order to extract still further TnBP and Triton X-45 with the oil .
- the third funnel bag is then hung up in order to allow for separation of a lower plasma phase and an upper TnBP and Triton X-45 containing oil phase .
- the lower plasma layer is drained by gravity through the outlet facility into a classical plasma storage bag.
- TnBP and Triton X-45 contents are measured in the plasma after each extraction step :
- the PT, PTT, INR (international normalized ratio) , and FVIII and FIX physiological functions are also determined at all steps :
- EXAMPLE 5 Viral inactivation of 200 ml recovered plasma with 1% TnBP and 1% Triton X-100
- Recovered plasma from one donation of about 200 ml is transferred into a sterile, single 200 ml viral inactivation bag according to Figure 1 and the bag is heated to 31 0 C +/- I 0 C .
- a 1 : 1 solution of pure tri (n-butyl) phosphate (TnBP) and Triton X-100 is pre-filled into a sterile syringe . Then, the TnBP/Triton X-IOO solution is added with the syringe (via the second port of the inactivation bag) slowly over 30 minutes to the plasma . The inactivation bag is under gentle shaking, such as using a platelet concentrate shaker device until a final concentration of 1% TnBP and 1% Triton X-100 of the total plasma weight is reached .
- TnBP tri (n-butyl) phosphate
- Triton X-100 Triton X-100
- the tubing of the inlet facility is heat-sealed in order to isolate the inactivation bag .
- the plasma is then transferred into a funnel bag according to Figure 2 containing 15 ml (i . e . 7.5 wt% with respect to the weight of the plasma) of pharmaceutical grade castor oil .
- the outlet facility of the viral inactivation bag is pierced with the spike of the inlet facility of the funnel bag and the TnBP and Triton X-100 containing plasma is transferred by gravity.
- the oil/plasma mixture is shaken vigorously until the formation of an emulsion for about one minute, then gently for 15 minutes at room temperature in order to extract TnBP and minor amounts of Triton X-100 using the oil .
- the funnel bag is then hung up in order to allow for separation of a lower plasma phase and an upper oil phase containing TnBP and minor amounts of Triton X-IOO .
- the lower layer is drained by gravity through the outlet facility into a second funnel bag containing 15 ml of pharmaceutical grade castor oil .
- the phase interface is detected with the naked eye .
- the oil/plasma mixture in the second funnel bag is shaken vigorously until the formation of an emulsion for about one minute , then gently for 15 minutes at room temperature in order to extract further TnBP and minor amounts of Triton X-100 with the oil .
- the second funnel bag is then hung up in order to allow for separation of a lower plasma phase and an upper oil phase containing TnBP and minor amounts of Triton X-100.
- the lower plasma layer is drained by gravity through the outlet facility into a third funnel bag containing 15 ml of pharmaceutical grade castor oil .
- the oil/plasma mixture in the third funnel bag is shaken vigorously until the formation of an emulsion for about one minute, then gently for 15 minutes at room temperature in order to extract still further TnBP and minor amounts of Triton X-100 with the oil .
- the third funnel bag is then hung up in order to allow for separation of a lower plasma phase and an upper oil phase containing TnBP and minor amounts of Triton X-100. Subsequent to the third oil extraction, the plasma is transferred to a centrifugation bag and centrifuged in a blood bank centrifuge at 3 , 900 rpm for 30 min at 20 0 C .
- the plasma is subj ected to column chromatography on a Cl8 chromatographic column to remove the major amount of Triton X-100.
- TnBP and Triton X-100 contents are measured in the plasma after each extraction step and after column chromatography :
- the PT, PTT, INR (international normalized ratio) , and FVIII and FIX physiological functions are also determined at all steps :
- Example 6 Viral inactivation of 200 ml recovered plasma with 2% TnBP at 37 0 C
- Recovered plasma from one donation of about 200 ml is transferred into a sterile , single 200 ml viral inactivation bag according to Figure 1 and the bag is heated to 37 °C +/ - 1°C .
- TnBP tri (n-butyl) phosphate
- the tubing of the inlet facility is heat-sealed in order to isolate the inactivation bag .
- the plasma is then transferred into a funnel bag according to Figure 2 containing 10 ml of pharmaceutical grade castor oil .
- a funnel bag containing 10 ml of pharmaceutical grade castor oil .
- the outlet facility of the viral inactivation bag is pierced with the spike of the inlet facility of the funnel bag and the TnBP containing plasma is transferred by gravity.
- the oil/plasma mixture is shaken vigorously until the formation of an emulsion for about one minute , then gently for 15 minutes at room temperature in order to extract TnBP using the oil .
- the funnel bag is then hung up for about 30 min in order to allow for separation of a lower plasma phase and an upper TnBP containing oil phase .
- the lower layer is drained by gravity through the outlet facility into a second funnel bag containing 15 ml of pharmaceutical grade castor oil .
- the phase interface is detected with a UV detector that is arranged on the level of the outlet facility of the first funnel bag.
- the oil/plasma mixture in the second funnel bag is shaken vigorously until the formation of an emulsion for about one minute, then gently for 15 minutes at room temperature in order to extract further TnBP with the oil .
- the second funnel bag is then hung up in order to allow for separation of a lower plasma phase and an upper TnBP containing oil phase .
- the lower plasma layer is drained by gravity through the outlet facility into a third funnel bag containing 15 ml of pharmaceutical grade castor oil .
- the oil/plasma mixture in the third funnel bag is shaken vigorously until the formation of an emulsion for about one minute, then gently for 15 minutes at room temperature in order to extract further TnBP with the oil .
- the third funnel bag is then hung up in order to allow for separation of a lower plasma phase and an upper TnBP containing oil phase . Subsequent to the third oil extraction, the plasma is subjected to clarifying centrifugation at 3 , 700 rpm for 30 min at 2O 0 C .
- the TnBP is measured in the plasma after each extraction step :
- the PT, APTT, INR (international normalized ratio) , and FVIII and FIX physiological functions are also determined at all steps
- EXAMPLE 7 Viral inactivation of 200 ml cryo-poor plasma with 1% TnBP and 1% Triton X-45
- TnBP and Triton X-45 contents are measured in the Cryo-poor plasma after each extraction step :
- the PT, APTT, INR (international normalized ratio) , FVII and FIX are also determined at all steps :
- EXAMPLE 8 Viral inactivation of 200 ml cryo-poor plasma with 1% TnBP and 1% Triton X-100.
- Cryo-poor plasma obtained from one donation of about 200 ml recovered plasma is transferred into a sterile, single 200 ml viral inactivation bag according to Figure 1 and the bag is heated to 31 0 C +/- I 0 C .
- a 1 : 1 solution of pure tri (n-butyl ) phosphate (TnBP) and Triton X-100 is pre-filled into a sterile syringe .
- the TnBP/Triton X-100 solution is added with the syringe (via the second port of the inactivation bag) slowly over 30 minutes to the cryo-poor plasma .
- the inactivation bag is under gentle shaking, such as using a platelet concentrate shaker device until a final concentration of 1% TnBP and 1% Triton X-100 of the total cryo-poor plasma weight is reached .
- the tubing of the inlet facility is heat-sealed in order to isolate the inactivation bag .
- the cryo-poor plasma is then transferred into a funnel bag according to Figure 2 containing 15 ml (i . e . 7.5 wt% with respect to the weight of the cryo-poor plasma) of pharmaceutical grade castor oil .
- the outlet facility of the viral inactivation bag is pierced with the spike of the inlet facility of the funnel bag and the TnBP and Triton X- 100 containing cryo-poor plasma is transferred by gravity.
- the oil/cryo-poor plasma mixture is shaken vigorously until the formation of an emulsion for about one minute , then gently for 15 minutes at room temperature in order to extract TnBP and minor amounts of Triton X-100 using the oil .
- the funnel bag is then hung up in order to allow for separation of a lower cryo-poor plasma phase and an upper oil phase containing TnBP and minor amounts of Triton X- 100.
- the lower layer is drained by gravity through the outlet facility into a second funnel bag containing 15 ml of pharmaceutical grade castor oil .
- the phase interface is detected with the naked eye .
- the oil/cryo-poor plasma mixture in the second funnel bag is shaken vigorously until the formation of an emulsion for about one minute, then gently for 15 minutes at room temperature in order to extract further TnBP and minor amounts of Triton X-100 with the oil .
- the second funnel bag is then hung up in order to allow for separation of a lower cryo-poor plasma phase and an upper oil phase containing TnBP and minor amounts of Triton X- 100.
- the lower cryo-poor plasma layer is drained by gravity through the outlet facility into a third funnel bag containing 15 ml of pharmaceutical grade castor oil .
- the oil/cryo-poor plasma mixture in the third funnel bag is shaken vigorously until the formation of an -emulsion for about one minute , then gently for 15 minutes at room temperature in order to extract still further TnBP and minor amounts of Triton X-100 with the oil .
- the third funnel bag is then hung up in order to .allow for separation of a lower plasma phase and an upper oil phase containing TnBP and minor amounts of Triton X-100.
- the plasma is transferred to a centrifugation bag and centrifuged in a blood bank centrifuge at 3 , 900 rpm for 30 min at 20 0 C .
- the plasma is subjected to column chromatography on a SDR chromatographic column to remove the maj or amount of Triton X-100.
- TnBP and Triton X-100 contents are measured in the plasma after each extraction step and after column chromatography:
- TnBP and Triton X-100 contents are measured in the Cryo-poor plasma after each extraction step and after column chromatography on SDR :
- the PT, APTT, INR (international normalized ratio) , FVII and FIX are also determined at all steps :
- the TnBP is measured in the Cryo-poor plasma after each extraction step :
- the PT, PTT, INR (international normalized ratio) , and FVIII and FIX physiological functions are also determined at all steps.
- EXAMPLE 10 Viral inactivation of 150 ml cryoprecipitate with 1% TnBP and 1% Triton X-45
- TnBP and Triton X-45 contents are measured in the cryoprecipitate after each extraction step :
- the PT, and FVIII , fibrinogen, and von Willebrand factor and FIX physiological functions are also determined at all steps :
- EXAMPLE 11 Viral inactivation of 150 ml cryoprecipitate with 1% TnBP and 1% Triton X-100
- TnBP and Triton X-100 contents are measured in the cryoprecipitate after each extraction step and after column chromatography:
- the FVIII , fibrinogen, and VWF physiological functions are also determined at all steps :
- EXAMPLE 12 Viral inactivation of 150 ml cryoprecipitate with 2% TnBP at 37 0 C
- the TnBP is measured in the cryoprecipitate after each extraction step :
- the FVIII , fibrinogen, and VWF physiological functions are also determined at all steps :
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- External Artificial Organs (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0604832-3A BRPI0604832A (en) | 2005-02-01 | 2006-02-01 | disposable pouch set for viral inactivation of biological fluids |
AU2006210161A AU2006210161B2 (en) | 2005-02-01 | 2006-02-01 | Set of disposable bags for viral inactivation of biological fluids |
JP2007552608A JP5230204B2 (en) | 2005-02-01 | 2006-02-01 | Set of disposable bags used for virus inactivation of biological fluids |
CA2565336A CA2565336C (en) | 2005-02-01 | 2006-02-01 | Set system of disposable bags for viral inactivation of biological fluids |
US11/579,163 US20070219524A1 (en) | 2005-02-01 | 2006-02-01 | Set of Disposable Bags for Viral Inactivation of Biological Fluids |
DK06723055.7T DK1845926T3 (en) | 2005-02-01 | 2006-02-01 | Set of disposable bags for virus inactivation of biological fluids |
EP06723055A EP1845926B1 (en) | 2005-02-01 | 2006-02-01 | Set of disposable bags for viral inactivation of biological fluids |
EGNA2006000998 EG25033A (en) | 2005-02-01 | 2006-10-18 | Set of disposable bags for viral inactivation of biological fluids. |
NO20064916A NO20064916L (en) | 2005-02-01 | 2006-10-27 | Set of disposable bags for viral activation of body fluids |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05290223A EP1685852A1 (en) | 2005-02-01 | 2005-02-01 | Set of disposable bags for viral inactivation of biological fluids |
EP05290223.6 | 2005-02-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006082115A1 true WO2006082115A1 (en) | 2006-08-10 |
Family
ID=34941923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/001455 WO2006082115A1 (en) | 2005-02-01 | 2006-02-01 | Set of disposable bags for viral inactivation of biological fluids |
Country Status (12)
Country | Link |
---|---|
US (1) | US20070219524A1 (en) |
EP (2) | EP1685852A1 (en) |
JP (1) | JP5230204B2 (en) |
CN (1) | CN1953728A (en) |
AU (1) | AU2006210161B2 (en) |
BR (1) | BRPI0604832A (en) |
CA (1) | CA2565336C (en) |
DK (1) | DK1845926T3 (en) |
EG (1) | EG25033A (en) |
NO (1) | NO20064916L (en) |
PT (1) | PT1845926E (en) |
WO (1) | WO2006082115A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009118331A1 (en) * | 2008-03-28 | 2009-10-01 | Research Foundation For Medical Devices | Method of viral inactivation of biological fluids by solvent/detergent-treatment |
EP2125042A1 (en) * | 2007-02-14 | 2009-12-02 | Research Foundation For Medical Devices | Preparation of virally inactivated biological fluids having high alpha-2-antiplasmin activity |
EP2399613A1 (en) | 2010-06-22 | 2011-12-28 | Research Foundation For Medical Devices | Fractionation of plasma using caprylic acid |
WO2018060522A1 (en) * | 2016-09-30 | 2018-04-05 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Method for the virus inactivation of a preparation of monoclonal antibodies |
WO2022195147A1 (en) * | 2021-03-18 | 2022-09-22 | Liquidpack, S.L. | Bag containing fluid products |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2077118A1 (en) * | 2008-01-07 | 2009-07-08 | Gwo Rei Biomedical Technology Corp. | Clottable concentrate of platelet growth factors and preparation method thereof |
KR101019106B1 (en) | 2008-11-28 | 2011-03-07 | 주식회사 중외 | A medicine container |
GB0922426D0 (en) * | 2009-12-22 | 2010-02-03 | Ge Healthcare Bio Sciences Ab | Containers for chromatography media |
ES2402144T3 (en) | 2010-05-25 | 2013-04-29 | Gwowei Technology Co., Ltd. | Inactivated platelet lysate containing depleted growth factors in PDGF and VEGF and their preparation procedure |
US9797871B2 (en) * | 2010-08-05 | 2017-10-24 | Ge Healthcare Bio-Sciences Ab | Method for storage and stabilization of a target substance |
US8506797B2 (en) * | 2011-04-10 | 2013-08-13 | Therapeutic Proteins International, LLC | Downstream bioprocessing device |
US9284346B2 (en) * | 2011-09-07 | 2016-03-15 | Therapeutic Proteins International, LLC | Preparative chromatography column and methods |
US9561893B2 (en) | 2013-12-05 | 2017-02-07 | Vascular Solutions, Inc. | System and method for freeze-drying and packaging |
WO2015154815A1 (en) * | 2014-04-10 | 2015-10-15 | Soulie Valérie | Machine for automated viral inactivation treatment of a biological fluid and associated kit |
CN104248643A (en) * | 2014-08-12 | 2014-12-31 | 中国人民解放军总医院 | Preparation device and preparation method of universal virus inactivation blood plasma |
US10806665B2 (en) * | 2016-01-18 | 2020-10-20 | Teleflex Life Sciences Limited | System and method for freeze-drying and packaging |
JP6983454B2 (en) | 2016-09-30 | 2021-12-17 | サイティバ・スウェーデン・アクチボラグ | Methods and systems for the transfer of separated resins |
AU2018228495B2 (en) * | 2017-03-03 | 2023-11-23 | Rich Technologies Holding Company, Llc | Device for preserving blood products and cellular cultures in a gas medium under pressure |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3872868A (en) * | 1973-09-27 | 1975-03-25 | Joel B Kline | Universal hospital container |
US4481189A (en) | 1982-04-14 | 1984-11-06 | New York Blood Center Inc. | Process for preparing sterilized plasma and plasma derivatives |
US4540573A (en) | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
US4789545A (en) | 1986-03-31 | 1988-12-06 | New York Blood Center, Inc. | Removal of lipid soluble process chemicals from biological materials by extraction with naturally occurring oils or synthetic substitutes thereof |
US5094960A (en) | 1988-10-07 | 1992-03-10 | New York Blood Center, Inc. | Removal of process chemicals from labile biological mixtures by hydrophobic interaction chromatography |
US5744038A (en) * | 1993-07-30 | 1998-04-28 | Aruba International Pty Ltd. | Solvent extraction methods for delipidating plasma |
US6099734A (en) * | 1998-07-08 | 2000-08-08 | Baxter International Inc. | Apparatus, membranes and methods for removing organic compounds from a biological fluid |
US20010010802A1 (en) * | 1998-08-28 | 2001-08-02 | Yehuda Tamari | Soft shell venous reservoir |
US6364864B1 (en) * | 1999-06-03 | 2002-04-02 | Baxter International Inc. | Plastic containers having inner pouches and methods for making such containers |
US20020094568A1 (en) * | 1998-01-06 | 2002-07-18 | Hei Derek J. | Batch devices for the reduction of compounds from biological compositions containing cells and methods of use |
WO2003078963A2 (en) * | 1999-07-29 | 2003-09-25 | Baxter International Inc. | Biological fluid sampling apparatus |
US20040170649A1 (en) * | 2000-06-29 | 2004-09-02 | Cham Bill E. | Method of treating and preventing infectious diseases via creation of a modified viral particle with immunogenic properties |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4258010A (en) * | 1975-11-19 | 1981-03-24 | Eszakmagyarorszagi Vegyimu_ vek | Solvent extraction apparatus |
US4170056A (en) * | 1976-03-25 | 1979-10-09 | Baxter Travenol Laboratories, Inc. | Blood filter |
IL51209A (en) * | 1976-03-25 | 1981-02-27 | Baxter Travenol Lab | Blood filter |
US4305443A (en) * | 1979-03-05 | 1981-12-15 | Baxter Travenol Laboratories, Inc. | Seal for flexible container having flexible, generally conical portions |
US4244409A (en) * | 1979-10-09 | 1981-01-13 | Abbott Laboratories | Collapsible solution container |
DE3531430A1 (en) * | 1985-09-03 | 1987-03-05 | Biotest Pharma Gmbh | METHOD FOR OBTAINING COMPONENTS FROM A LIQUID WITH COMPONENTS PRESENT IN AREAS SEPARATELY SEPARATED |
US4806252A (en) * | 1987-01-30 | 1989-02-21 | Baxter International Inc. | Plasma collection set and method |
US4909940A (en) * | 1987-12-30 | 1990-03-20 | New York Blood Center, Inc. | Extraction of process chemicals from labile biological mixtures with organic alcohols or with halogenated hydrocarbons |
DE68902698C5 (en) * | 1988-06-23 | 2005-07-14 | Asahi Medical Co. Ltd. | Method for separating blood into blood components and unit for separating blood components. |
JP2838725B2 (en) * | 1990-05-02 | 1998-12-16 | テルモ株式会社 | Blood collection equipment |
JP2576744B2 (en) * | 1991-11-05 | 1997-01-29 | 日揮株式会社 | Liquid-liquid contact tower |
US5520885A (en) * | 1993-01-19 | 1996-05-28 | Thermogenesis Corporation | Fibrinogen processing apparatus, method and container |
JPH0852196A (en) * | 1994-08-09 | 1996-02-27 | Material Eng Tech Lab Inc | Transfusion container having connecting port for medicine |
US6019751A (en) * | 1998-01-20 | 2000-02-01 | Bracco Research Usa | Universal connector and a medical container |
AU749358B2 (en) * | 1998-01-23 | 2002-06-27 | Pall Corporation | Biological fluid treatment system |
US6565802B1 (en) * | 1999-06-03 | 2003-05-20 | Baxter International Inc. | Apparatus, systems and methods for processing and treating a biological fluid with light |
SE9902388D0 (en) * | 1999-06-23 | 1999-06-23 | Pharmacia & Upjohn Ab | Method for purification of proteins |
US6518406B1 (en) * | 1999-06-23 | 2003-02-11 | Octapharma Ag | Method for purification of proteins |
FR2799986B1 (en) * | 1999-10-20 | 2001-11-23 | Maco Pharma Sa | FILTER UNIT OF A VIRUCID SUBSTANCE |
DE19959230C1 (en) * | 1999-12-08 | 2001-04-05 | Fresenius Medical Care De Gmbh | Two-sheet pouch, used as disposable haemodialysis container, comprises top and bottom closed by convex weld seams and is repeatedly folded parallel to its vertical axis |
IL136552A (en) * | 2000-06-05 | 2005-05-17 | Omrix Biopharmaceuticals Ltd | Method for the inactivation of viruses by a solvent - detergent combination and by nanofiltration |
CN1376520A (en) * | 2002-02-28 | 2002-10-30 | 华兰生物工程股份有限公司 | Process for deactivating freeze dried human plasma virus |
GB0216002D0 (en) * | 2002-07-10 | 2002-08-21 | Nat Blood Authority | Process and composition |
PT2368565E (en) * | 2003-07-03 | 2015-10-19 | Hdl Therapeutics Inc | Enrichment of pre-beta high density lipoproteins |
CN101005859B (en) * | 2004-06-29 | 2012-08-15 | 利莱恩斯生命科学有限公司 | Process for preparation of virus-safe biological fluids |
-
2005
- 2005-02-01 EP EP05290223A patent/EP1685852A1/en not_active Withdrawn
-
2006
- 2006-02-01 WO PCT/EP2006/001455 patent/WO2006082115A1/en active Application Filing
- 2006-02-01 BR BRPI0604832-3A patent/BRPI0604832A/en not_active IP Right Cessation
- 2006-02-01 PT PT67230557T patent/PT1845926E/en unknown
- 2006-02-01 CN CNA2006800002000A patent/CN1953728A/en active Pending
- 2006-02-01 US US11/579,163 patent/US20070219524A1/en not_active Abandoned
- 2006-02-01 DK DK06723055.7T patent/DK1845926T3/en active
- 2006-02-01 CA CA2565336A patent/CA2565336C/en not_active Expired - Fee Related
- 2006-02-01 JP JP2007552608A patent/JP5230204B2/en not_active Expired - Fee Related
- 2006-02-01 EP EP06723055A patent/EP1845926B1/en not_active Not-in-force
- 2006-02-01 AU AU2006210161A patent/AU2006210161B2/en not_active Ceased
- 2006-10-18 EG EGNA2006000998 patent/EG25033A/en active
- 2006-10-27 NO NO20064916A patent/NO20064916L/en not_active Application Discontinuation
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3872868A (en) * | 1973-09-27 | 1975-03-25 | Joel B Kline | Universal hospital container |
US4481189A (en) | 1982-04-14 | 1984-11-06 | New York Blood Center Inc. | Process for preparing sterilized plasma and plasma derivatives |
US4540573A (en) | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
US4789545A (en) | 1986-03-31 | 1988-12-06 | New York Blood Center, Inc. | Removal of lipid soluble process chemicals from biological materials by extraction with naturally occurring oils or synthetic substitutes thereof |
US5094960A (en) | 1988-10-07 | 1992-03-10 | New York Blood Center, Inc. | Removal of process chemicals from labile biological mixtures by hydrophobic interaction chromatography |
US5744038A (en) * | 1993-07-30 | 1998-04-28 | Aruba International Pty Ltd. | Solvent extraction methods for delipidating plasma |
US20020094568A1 (en) * | 1998-01-06 | 2002-07-18 | Hei Derek J. | Batch devices for the reduction of compounds from biological compositions containing cells and methods of use |
US6099734A (en) * | 1998-07-08 | 2000-08-08 | Baxter International Inc. | Apparatus, membranes and methods for removing organic compounds from a biological fluid |
US20010010802A1 (en) * | 1998-08-28 | 2001-08-02 | Yehuda Tamari | Soft shell venous reservoir |
US6364864B1 (en) * | 1999-06-03 | 2002-04-02 | Baxter International Inc. | Plastic containers having inner pouches and methods for making such containers |
WO2003078963A2 (en) * | 1999-07-29 | 2003-09-25 | Baxter International Inc. | Biological fluid sampling apparatus |
US20040170649A1 (en) * | 2000-06-29 | 2004-09-02 | Cham Bill E. | Method of treating and preventing infectious diseases via creation of a modified viral particle with immunogenic properties |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2125042A1 (en) * | 2007-02-14 | 2009-12-02 | Research Foundation For Medical Devices | Preparation of virally inactivated biological fluids having high alpha-2-antiplasmin activity |
WO2009118331A1 (en) * | 2008-03-28 | 2009-10-01 | Research Foundation For Medical Devices | Method of viral inactivation of biological fluids by solvent/detergent-treatment |
US20110033554A1 (en) * | 2008-03-28 | 2011-02-10 | Research Foundation For Medical Devices | Method of Viral Inactivation of Biological Fluids |
JP2011515170A (en) * | 2008-03-28 | 2011-05-19 | リサーチ ファンデーション フォー メディカル デバイシズ | Method for inactivating virus in biological fluid by solvent / surfactant treatment |
EP2399613A1 (en) | 2010-06-22 | 2011-12-28 | Research Foundation For Medical Devices | Fractionation of plasma using caprylic acid |
WO2011161107A1 (en) | 2010-06-22 | 2011-12-29 | Research Foundation For Medical Devices | Small-pool fractionation of immunoglobulin g using caprylic acid and disposable equipment |
WO2018060522A1 (en) * | 2016-09-30 | 2018-04-05 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Method for the virus inactivation of a preparation of monoclonal antibodies |
FR3056912A1 (en) * | 2016-09-30 | 2018-04-06 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | PROCESS FOR VIRAL INACTIVATION OF MONOCLONAL ANTIBODY PREPARATION |
FR3056913A1 (en) * | 2016-09-30 | 2018-04-06 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | PROCESS FOR VIRAL INACTIVATION OF MONOCLONAL ANTIBODY PREPARATION |
WO2022195147A1 (en) * | 2021-03-18 | 2022-09-22 | Liquidpack, S.L. | Bag containing fluid products |
Also Published As
Publication number | Publication date |
---|---|
JP5230204B2 (en) | 2013-07-10 |
DK1845926T3 (en) | 2013-03-18 |
CA2565336C (en) | 2013-04-16 |
BRPI0604832A (en) | 2007-12-18 |
PT1845926E (en) | 2013-03-05 |
EP1685852A1 (en) | 2006-08-02 |
EP1845926A1 (en) | 2007-10-24 |
NO20064916L (en) | 2007-02-14 |
JP2008528148A (en) | 2008-07-31 |
EP1845926B1 (en) | 2013-01-02 |
US20070219524A1 (en) | 2007-09-20 |
CA2565336A1 (en) | 2006-08-10 |
CN1953728A (en) | 2007-04-25 |
AU2006210161B2 (en) | 2011-10-13 |
EG25033A (en) | 2011-06-26 |
AU2006210161A1 (en) | 2006-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2565336C (en) | Set system of disposable bags for viral inactivation of biological fluids | |
EP2271374B1 (en) | Method of viral inactivation of biological fluids by solvent/detergent-treatment | |
EP0322786B1 (en) | Extraction of process chemicals from labile biological mixtures with halogenated hydrocarbons | |
US20210260114A1 (en) | Cryoprecipitate compositions and methods of preparation thereof | |
AU621148B2 (en) | Removal of process chemicals from labile biological mixtures by hydrophobic interaction chromatography | |
US6468733B2 (en) | Method of the inactivation of viruses by a solvent-detergent combination and nanofiltration | |
CN101005859B (en) | Process for preparation of virus-safe biological fluids | |
ES2474740T3 (en) | System to obtain immunoglobulin from blood | |
ES2232345T3 (en) | PROCEDURE FOR THE INACTIVATION OF VIRUSES. | |
LT et al. | EINWEGBEUTELSET ZUR VIRALEN INAKTIVIERUNG VON BIOLOGISCHEN FLÜSSIGKEITEN ENSEMBLE DE SACS JETABLE DESTINES A L’INACATIVATION VIRALE DES FLUIDES BIOLOGIQUES | |
Heimburger et al. | Factor VIII concentrate—now free from hepatitis risk: progress in the treatment of haemophilia | |
Rezvan et al. | Safety of blood and plasma derivatives: pathogen reducing technologies | |
Radosevich | Research and development commitments in an integrated plasma collection and plasma fractionation environment | |
Baikar et al. | Separation of antihemophilic factor VII from human plasma by column chromatography | |
Allersma et al. | Preparation of lyophilized heat-treated cryoprecipitates from a small pool of plasma obtained by apheresis | |
Benny et al. | Influence of heat treatment on FVIII: C recovery from freeze dried cryoprecipitate. | |
Dichtelmüller | Ensuring Virus Safety of Plasma Products | |
EA045773B1 (en) | APPLICATION OF PATHOGENE-INACTIVATED CRYOPRECIPITATE COMPOSITION FOR INFUSION TO A PATIENT | |
WO2004087220A1 (en) | Isolation of a protein from a natural source in sterile form | |
AU2013204469A1 (en) | Systems and methods for obtaining immunoglobulin from blood |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006723055 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006210161 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2565336 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007552608 Country of ref document: JP Ref document number: 200680000200.0 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2006210161 Country of ref document: AU Date of ref document: 20060201 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006210161 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007219524 Country of ref document: US Ref document number: 11579163 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 11579163 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2006723055 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0604832 Country of ref document: BR |